Kirk Nielsen focuses on medical device investing at Versant Ventures. He joined Versant from Medtronic, where he was a sales representative in the company's Cardiac Rhythm Management division. Previously, he worked in marketing & business development for Medtronic and for Fluidigm (a Versant portfolio company), and he has also served as a strategy consultant at Bain & Company, where he advised clients in healthcare, private equity, and other industries. Prior to his business career, Kirk was a professional hockey player. At Versant, Kirk has been actively involved with Cameron Health (sold), Lutonix (sold), CardiAQ, Helical Solutions, Holaira, Inceptus Medical, Metavention, Sequent Medical, and Zyga Technology. Based in Minneapolis, he also leads the firm’s activities in the Midwest. Kirk earned a BA in biology with honors from Harvard College, where he won the John P. Reardon, Jr. award as the school’s most outstanding scholar-athlete, and an MBA from Harvard Business School, where he was a Baker Scholar.